keyword
MENU ▼
Read by QxMD icon Read
search

Hyperparathyroid

keyword
https://www.readbyqxmd.com/read/29912988/severe-secondary-hyperparathyroidism-in-patients-on-haemodialysis-is-associated-with-a-high-initial-serum-parathyroid-hormone-and-beta-crosslaps-level-results-from-an-incident-cohort
#1
Guillaume Jean, Marie Hélène Lafage-Proust, Jean Claude Souberbielle, Sylvain Lechevallier, Patrik Deleaval, Christie Lorriaux, Jean Marc Hurot, Brice Mayor, Manolie Mehdi, Charles Chazot
BACKGROUND: Secondary hyperparathyroidism (SHPT) is a frequent complication of renal disease and most commonly occurs in patients on haemodialysis (HD) with metabolic, vascular, endocrine, and bone complications. The aim of this study was to analyze the evolution of mineral metabolism parameters during the first 36 months of HD treatment and identify the initial factors associated with severe SHPT. METHODS: Serum parathyroid hormone (PTH), calcium and phosphate levels were measured monthly; bone-specific alkaline phosphatase (b-ALP) and beta-CrossLaps (CTX) were measured biannually...
2018: PloS One
https://www.readbyqxmd.com/read/29910605/role-of-etelcalcetide-in-the-management-of-secondary-hyperparathyroidism-in-hemodialysis-patients-a-review-on-current-data-and-place-in-therapy
#2
REVIEW
Claudia Friedl, Emanuel Zitt
Secondary hyperparathyroidism (sHPT) is a frequently occurring severe complication of advanced kidney disease. Its clinical consequences include extraskeletal vascular and valvular calcifications, changes in bone metabolism resulting in renal osteodystrophy, and an increased risk of cardiovascular morbidity and mortality. Calcimimetics are a cornerstone of parathyroid hormone (PTH)-lowering therapy, as confirmed by the recently updated 2017 Kidney Disease: Improving Global Outcomes chronic kidney disease - mineral and bone disorder clinical practice guidelines...
2018: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/29909163/update-on-multiple-endocrine-neoplasia-type-1-and-2
#3
Abdallah Al-Salameh, Camille Baudry, Régis Cohen
Multiple endocrine neoplasia type 1 is a rare genetic syndrome, characterized by the co-occurrence, in the same individual or in related individuals of the same family, of hyperparathyroidism, duodenopancraetic neuroendocrine tumors, pituitary adenomas, adrenocortical tumors, and neuroendocrine tumors (carcinoids) in the thymus, the bronchi, or the stomach. Multiple endocrine neoplastic type 2 is a rare genetic syndrome, characterized by the familial occurrence of medullary thyroid carcinoma either isolated or associated with pheochromocytoma, primary hyperparathyroidism, or typical features (Marfanoid habitus, mucosal neuromas)...
June 13, 2018: La Presse Médicale
https://www.readbyqxmd.com/read/29908897/impacts-of-parathyroidectomy-on-calcium-and-phosphorus-metabolism-disorder-arterial-calcification-and-arterial-stiffness-in-haemodialysis-patients
#4
Zhuo Gao, Xiaomei Li, Jing Miao, Lide Lun
BACKGROUND: Secondary hyperparathyroidism (SHPT) and calcium and phosphorus metabolism disorder are important complications in haemodialysis patients. Parathyroidectomy (PTX) may prevent or delay the progress of vascular calcification in haemodialysis patients. OBJECTIVE: To investigate the impacts of PTX on calcium and phosphorus metabolism, arterial calcification and arterial stiffness in haemodialysis patients with SHPT. METHODS: Twenty-one SHPT-haemodialysis patients were selected for PTX...
June 13, 2018: Asian Journal of Surgery
https://www.readbyqxmd.com/read/29907149/changes-in-bone-mineral-density-after-total-parathyroidectomy-without-autotransplantation-in-the-end-stage-renal-disease-patients-with-secondary-hyperparathyroidism
#5
Li Fang, Jining Wu, Jing Luo, Ping Wen, Mingxia Xiong, Jinlong Cao, Xiaolan Chen, Junwei Yang
BACKGROUND: The patients with secondary hyperparathyroidism (SHPT) usually had reduced bone mineral density, which might lead to a substantial increase in osteoporosis, fracture and mortality. Although surgical intervention is effective in reducing parathyroid hormone (PTH) levels in suitable candidates refractory to medical therapy, the effect of surgery on bone mass changes still requires further evaluation. Thus, the aim of this study was to evaluate the characteristics of BMD changes after total parathyroidectomy (PTX) without autotransplantation and its associated factors...
June 15, 2018: BMC Nephrology
https://www.readbyqxmd.com/read/29905968/skeletal-consequences-of-nephropathic-cystinosis
#6
Pablo Florenzano, Carlos Ferreira, Galina Nesterova, Mary Scott Ramnitz, Sri Harsha Tella, Luis Fernandez de Castro, Sydney M Brown, Adom Whitaker, Renata C Pereira, Dorothy Bulas, Rachel I Gafni, Isidro B Salusky, William A Gahl, Michael T Collins
Nephropathic cystinosis is a rare lysosomal storage disorder. Patients present in the first year of life with renal Fanconi syndrome that evolves to progressive chronic kidney disease (CKD). Despite the multiple risk factors for bone disease, the frequency and severity of skeletal disorders in nephropathic cystinosis have not been described. We performed systematic bone and mineral evaluations of subjects with cystinosis seen at the NIH (N = 30), including history and physical examination, serum and urine biochemistries, DXA, vertebral fracture assessment, skeletal radiographs, and renal ultrasound...
June 15, 2018: Journal of Bone and Mineral Research: the Official Journal of the American Society for Bone and Mineral Research
https://www.readbyqxmd.com/read/29903718/calcitriol-accelerates-vascular-calcification-irrespective-of-vitamin-k-status-in-a-rat-model-of-ckd-with-hyperphosphatemia-and-secondary-hyperparathyroidism
#7
Kristin M McCabe, Jason G Zelt, Martin Kaufmann, Kimberly Laverty, Emilie Ward, Henry Barron, Glenville Jones, Michael A Adams, Rachel M Holden
Patients with chronic kidney disease have a markedly increased risk for developing cardiovascular disease. Non-traditional risk factors, such as increased phosphate retention, and deficiencies in vitamins D and K metabolism, likely play key roles in the development of vascular calcification during CKD progression. Calcitriol (1,25-(OH)2-D3) is a key transcriptional regulator of Matrix Gla protein (MGP), a vitamin K dependent protein that inhibits vascular calcification. The objective of this study was to determine if calcitriol treatment could inhibit the development of vascular calcification and if this inhibition was dependent on vitamin K status in a rat model of CKD...
June 14, 2018: Journal of Pharmacology and Experimental Therapeutics
https://www.readbyqxmd.com/read/29903510/quality-of-life-in-multiple-endocrine-neoplasia-type-2a-compared-with-normative-and-disease-populations
#8
Michael N Mongelli, Benjamin J Peipert, Sneha Goswami, Irene Helenowski, Susan E Yount, Cord Sturgeon
BACKGROUND: Patient-reported outcomes are measured in chronic disease states to inform intervention and management decisions while minimizing negative outcomes. We hypothesized that health-related quality of life in patients with multiple endocrine neoplasia type 2A would be worse than the general US population but similar to other chronic diseases. METHODS: Adults ≥18 years with multiple endocrine neoplasia type 2A were recruited to complete the Patient-Reported Outcomes Measurement Information System 29-item questionnaire (n = 45)...
June 11, 2018: Surgery
https://www.readbyqxmd.com/read/29900589/mineral-and-bone-disorders-in-conventional-hemodialysis-challenges-and-solutions
#9
Takayuki Hamano
Despite the advent of cinacalcet and noncalcium-containing phosphate binders, controlling the progression of vascular calcification (VC) is still challenging. Recent reports demonstrate that carbamylation driven by high urea concentration aggravates VC, suggesting the importance of adequate dialysis in retarding its progression. Theoretically, other promising measures include the use of iron-based phosphate binders, vitamin K, and magnesium supplements, which should be investigated in future randomized controlled trials (RCTs), ideally with hard outcomes...
June 13, 2018: Seminars in Dialysis
https://www.readbyqxmd.com/read/29899992/successful-use-of-cinacalcet-to-treat-parathyroid-related-hypercalcemia-in-two-pediatric-patients
#10
E Mogas, A Campos-Martorell, M Clemente, L Castaño, A Moreno-Galdó, D Yeste, A Carrascosa
Two pediatric patients with different causes of hyperparathyroidism are reported. First patient is a 13-year-old male with severe hypercalcemia due to left upper parathyroid gland adenoma. After successful surgery, calcium and phosphate levels normalized, but parathormone levels remained elevated. Further studies revealed a second adenoma in the right gland. The second patient is a 13-year-old female with uncommon hypercalcemia symptoms. Presence of pathogenic calcium-sensing receptor gene ( CASR ) mutation was found, resulting in diagnosis of symptomatic familial hypocalciuric hypercalcemia...
2018: Endocrinology, Diabetes & Metabolism Case Reports
https://www.readbyqxmd.com/read/29898699/rapid-calcium-loss-may-cause-arrhythmia-in-hemofiltration-with-regional-citrate-anticoagulation-a-case-report
#11
Buyun Wu, Jing Wang, Guang Yang, Changying Xing, Huijuan Mao
BACKGROUND: Renal replacement therapy (RRT) with regional citrate anticoagulation (RCA) is an important therapeutic approach for refractory hypercalcemia complicated with renal failure. However, RCA has the potential to induce arrhythmia caused by rapid calcium loss. We report a case of arrhythmia associated with rapid calcium loss during RCA-RRT. CASE PRESENTATION: A 51-year-old man with hypercalcemia, primary hyperparathyroidism, and acute kidney injury was treated by predilutional-RCA-hemofiltration at a rate of 4...
June 14, 2018: BMC Nephrology
https://www.readbyqxmd.com/read/29897580/recent-topics-around-multiple-endocrine-neoplasia-type-1
#12
Stephen J Marx
Introduction: Multiple endocrine neoplasia type 1 (MEN1) is complex with regard to clinical expressions, management, and molecular pathways. Advances are being made broadly and in focused aspects. Selected topics are presented for their developments since publication of the most recent MEN1 consensus guidelines 6 years ago. Methods: Topics were selected for clinical impact or broad interest or both. For each topic, information was obtained from original reports and reviews...
April 1, 2018: Journal of Clinical Endocrinology and Metabolism
https://www.readbyqxmd.com/read/29896462/subchondral-bone-restoration-of-supra-acetabular-brown-tumor-secondary-to-parathyroid-carcinoma-a-case-report
#13
Yong-Jin Park, Taek-Rim Yoon, Kyung-Soon Park, Jee-Wook Ko
The causes of osteolytic lesions found in radiological examinations are not quite certain. Therefore, to determine the appropriate treatment method, various approaches and analyzes are required to find the real cause. Hyperparathyroidism is one of the diseases which forms osteolytic bone lesions so-called brown tumor. A 55-year-old woman who had painful osteolytic bone lesions in both hip joint areas was diagnosed as parathyroid carcinoma after serial work-up. She underwent parathyroidectomy and follow-up imaging showed a decrease in brown tumor size and bone consolidation in the subchondral bone destruction area...
June 2018: Hip & Pelvis
https://www.readbyqxmd.com/read/29895021/metabolic-syndrome-in-parathyroid-diseases
#14
Sabrina Corbetta, G Mantovani, A Spada
Parathyroid glands are the main regulator of body mineral metabolism through parathormone (PTH) actions on bone and kidney. Experimental evidence suggests that PTH may have non-classical target organs such as adipose tissue, arterial vascular wall, cardiac muscle cells, and adrenal cortex cells, where it may play a role in controlling body energy, blood pressure, and metabolism. Cardiometabolic features have been investigated in the wide spectrum of clinical parathyroid disorders, from hyperparathyroidism to pseudohypoparathyroidism and hypoparathyroidism...
2018: Frontiers of Hormone Research
https://www.readbyqxmd.com/read/29888149/severe-acute-pancreatitis-as-an-index-clinical-manifestation-of-parathyroid-adenoma
#15
Tagore Sunkara, Megan E Caughey, Prashanth Rawla, Krishna Sowjanya Yarlagadda, Vinaya Gaduputi
Hypercalcemia due to primary or secondary hyperparathyroidism is a rare and obscure cause of acute pancreatitis. Although a rare occurrence to begin with, hyperparathyroidism commonly manifests with symptoms of hypercalcemia. Thus, it would reason that a patient might develop pancreatitis by way of hypercalcemia due to primary or secondary hyperparathyroidism. We present a case of an 88-year-old female with acute pancreatitis and only after an extensive work-up, was it determined that her severe acute pancreatitis resulted from primary hyperparathyroidism caused by a left parathyroid adenoma...
April 7, 2018: Curēus
https://www.readbyqxmd.com/read/29886668/-clinical-analysis-of-reoperation-for-secondary-hyperparathyroidism
#16
Z Hua, L Zhang, C Li, Z L Deng, L Yao
Objective: To investigate the safety and efficacy for reoperation after parathyroidectomy for persistent and recurrent secondary hyperparathyroidism (HPT). Methods: Totally 10 patients with persistent or recurrent HPT who underwent parathyroidectomy reoperation at Department of General Surgery, China-Japan Friendship Hospital from April 2001 to October 2012 were selected. Among them, 6 were male and 4 were female with age of (46.9±7.7) years (range: 36 to 57 years). There were 8 cases of persistent HPT and 4 cases of recurrent HPT...
June 1, 2018: Zhonghua Wai Ke za Zhi [Chinese Journal of Surgery]
https://www.readbyqxmd.com/read/29883066/parathyroid-hormone-and-bone-in-dialysis-patients
#17
REVIEW
Junichiro James Kazama, Minako Wakasugi
Bone maintains extracellular calcium levels through a system called bone remodeling. Parathyroid hormone (PTH) is the major initiator of this system, which is secreted by the information through calcium sensing receptor in parathyroid cells. PTH modifies calcified bone morphology through a process of its bone action. Therefore, extremely hyperactivated parathyroid function seen in patients with chronic kidney disease has been considered to have a negative impact on the bone mechanical properties. While skeletal deformities and fragility fractures were common among dialysis patients up to the 1970s, after which methods for the treatment of hyperparathyroidism were developed, we now seldom encounter those cases with severe secondary hyperparathyroidism in Japan...
June 2018: Therapeutic Apheresis and Dialysis
https://www.readbyqxmd.com/read/29879891/denosumab-induced-normocalcemic-hyperparathyroidismin-in-a-woman-with-postmenopausal-osteoporosis-and-normal-renal-function
#18
Elias E Mazokopakis
Elevations in serum parathyroid hormone (PTH) levels after denosumab administration have been described in medical literature among patients with renal impairment or intestinal malabsortion syndromes. We present the first case of denosumab-induced normocalcemic hyperparathyroidism in a woman with postmenopausal osteoporosis without renal impairment or malabsorption syndrome.
June 7, 2018: Current Drug Safety
https://www.readbyqxmd.com/read/29879737/correction-familial-hyperparathyroidism-disorders-of-growth-and-secretion-in-hormone-secretory-tissue
#19
Stephen J Marx, Delmar Muniz Lourenço
No abstract text is available yet for this article.
November 2017: Hormone and Metabolic Research, Hormon- und Stoffwechselforschung, Hormones et Métabolisme
https://www.readbyqxmd.com/read/29879701/treatment-based-on-cinacalcet-reduces-oxidative-stress-in-hemodialysis-patients-with-secondary-hyperparathyroidism
#20
Piotr Kuczera, Marcin Adamczak, Grzegorz Machnik, Boguslaw Okopien, Andrzej Wiecek
BACKGROUND/AIMS: Oxidative stress is one of the leading factors contributing to increased mortality in patients with chronic kidney disease (CKD) and secondary hyperparathyroidism (sHPT). Cinacalcet is now commonly used in the treatment of sHPT in patients with CKD. The aim of this study was to assess the influence of treatment with cinacalcet on the oxidative stress markers in patients on hemodialysis with sHPT. METHODS: In 58 hemodialysed patients with sHPT (parathyroid hormone [PTH] > 300 pg/mL) plasma Advanced Oxidation Protein Products (AOPP), serum total antioxidant capacity - ImAnOx (TAS/TAC), serum PTH, calcium and phosphate concentrations were assessed before the first dose of cinacalcet and after 6 months of treatment...
June 7, 2018: Nephron
keyword
keyword
474
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"